NCT05337267View on ClinicalTrials.gov

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

May 24, 2023

Study Completion Date

July 24, 2023

Conditions
Healthy Male Subjects
Interventions
DRUG

sintilimab (after the change)

0.3mg/kg，I.V.，single dose

DRUG

sintilimab (before the change)

0.3mg/kg，I.V.，single dose

Trial Locations (1)

410006

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY